HTD-1801 is under clinical development by HighTide Therapeutics and currently in Phase II for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). According to GlobalData, Phase II drugs for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HTD-1801’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HTD-1801 (berberine ursodeoxycholate) is under development for the treatment of primary sclerosing cholangitis (PSC), primary biliary cholangitis, type 2 diabetes comorbid with non-alcoholic fatty liver disease, liver fibrosis, severe hypertriglyceridemia (SHTG) and non-alcoholic steatohepatitis. The drug candidate is a new molecular entity consisting of an ionic salt of two active moieties. It is administered through oral route as a tablet. It was also under development for hypercholesterolemia.
HighTide Therapeutics overview
HighTide Therapeutics., is a biopharmaceutical company focused on discovering and developing novel drugs to treat chronic liver diseases, gastrointestinal diseases and metabolic disorders. The company is headquartered in China.
For a complete picture of HTD-1801’s drug-specific PTSR and LoA scores, buy the report here.